SCHEMBL25567220

SCHEMBL25567220

C#C[C@@]1(CO)CC[C@H](n2ccc(N)nc2=O)O1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3A Q14432 3/20 0.48
LMNA P02545 3/20 0.48
CACNA1F O60840 2/20 0.48
ALB P02768 2/20 0.48
MAPT P10636 2/20 0.48
CACNA1D Q01668 2/20 0.48
CACNA1S Q13698 2/20 0.48
CACNA1C Q13936 2/20 0.48
PDE4D Q08499 1/20 0.45
SLC29A1 Q99808 1/20 0.45
THRB P10828 1/20 0.42
MTOR P42345 1/20 0.42
MDM2 Q00987 1/20 0.42
NCOA1 Q15788 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
POLG P54098 2/20 0.37
POLB P06746 1/20 0.37
NT5E P21589 2/20 0.34
ABL1 P00519 1/20 0.34
RIN1 Q13671 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22110743 1.00 PDE3A (0.48) PDE3ALMNACACNA1FALBMAPT
SCHEMBL30174086 1.00 PDE3A (0.48) PDE3ALMNACACNA1FALBMAPT
SCHEMBL9548861 0.89 PDE3A (0.48) PDE3ALMNACACNA1FALBMAPT
SCHEMBL22110549 0.87 PDE3A (0.47) PDE3ALMNACACNA1FALBMAPT
SCHEMBL22110480 0.85 PDE3A (0.45) PDE3ALMNACACNA1FALBMAPT
SCHEMBL9548743 0.82 PDE3A (0.53) PDE3ALMNACACNA1FALBMAPT
SCHEMBL13843893 0.81 PDE3A (0.52) PDE3ALMNACACNA1FALBMAPT
SCHEMBL23808317 0.80 PDE3A (0.51) PDE3ALMNACACNA1FALBMAPT
SCHEMBL12840917 0.80 PDE3A (0.51) PDE3ALMNACACNA1FALBMAPT
SCHEMBL20879403 0.79 PDE3A (0.50) PDE3ALMNACACNA1FALBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3013340-B9 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN PHARMACEUTICALS INC (US) 2023-10-04 EP disclosed
US-20230295212-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE ROME THERAPEUTICS INC (US) 2023-09-21 US disclosed
EP-3013340-B1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF JANSSEN BIOPHARMA INC (US) 2023-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295212-A1 COMPOUNDS AND METHODS FOR TREATING DISEASE EHMT1, POLRMT, RNASE1 PDE3A 4016/4885LMNA 2032/4885CACNA1F 1035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.